查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1863246

抗菌素抗药性监测市场：按产品、技术、应用和最终用户划分－2025-2032年全球预测

Antimicrobial Resistance Surveillance Market by Offering, Technology, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，抗菌素抗药性监测市场将成长至 100.1 亿美元，复合年增长率为 6.70%。

主要市场统计数据
基准年 2024 59.6亿美元
预计年份：2025年 63.6亿美元
预测年份：2032年 100.1亿美元
复合年增长率 (%) 6.70%

引人入胜的引言将抗菌素抗药性监测定位为临床、技术和系统层面的紧迫优先事项，需要综合诊断和数据。

抗菌药物抗药性监测处于临床紧迫性、技术进步和公共卫生策略的交汇点，需要协调一致的实施，以清晰阐明挑战和不断变化的应对情况。本初步评估总结了协调监测对于维持治疗效果至关重要的原因。细菌病原体抗药性的不断增强正在重塑诊断重点，加速了对快速表型和基因型检测的需求，并迫使检查室和卫生系统重新思考如何在其网路中收集、分析和共用数据。除了临床意义之外，监测系统在食品安全、环境监测和流行病学情报方面也日益发挥核心作用，扩大了相关人员的范围，并强化了对可互通数据标准和安全资讯交流的需求。

对重塑全球抗菌素抗药性监测系统的关键技术、操作和政策主导变革进行了深入分析。

抗菌药物抗药性监测格局正经历着一场变革性的转变，其驱动因素包括技术的成熟、政策的调整以及相关人员期望的转变；本节将详细阐述这些关键的变革驱动因素。快速表型检测和高效能定序技术的进步缩短了从检体到可操作结果的时间，从而能够更精准地管理抗菌药物，并更早发现新出现的抗药性模式。同时，数位健康平台和检查室资讯系统促进了临床、公共卫生、食品安全和环境等领域之间更丰富的数据协作，强化了从孤立的检测事件向持续监测的转变。这些技术变革与日益严格的监管以及对资料透明度不断增长的期望相辅相成，促使各组织加强检验流程并投资于互通性标准。

全面评估近期关税变化对整个监测生态系统采购趋势、供应弹性策略和营运计画的影响

2025年生效的一系列关税措施的累积效应，为诊断试剂、试剂和检测设备的采购计算引入了新的变数。本节不进行数值预测，而是着重分析其实际影响。更高的进口关税和相关的贸易执法行动，加剧了依赖跨境供应链获取关键耗材和复杂设备的实验室和医疗系统的成本压力。为此，采购团队和供应机构日益重视采购多元化、本地製造伙伴关係以及库存优化策略，旨在减少对单一国家的依赖。同时，这些贸易变化也提升了基于服务的供应模式和试剂租赁项目的吸引力，这些模式和项目能够缓解设施资本支出的波动。

详细的細項分析揭示了产品供应、技术、应用领域和最终用户需求如何共同决定监控优先顺序和采购行为。

关键细分市场分析揭示了产品技术、应用和最终用户等不同维度如何交织影响抗菌药物抗药性监测的采购优先顺序、工作流程和投资选择。市场分析依产品类型划分，涵盖耗材和试剂、仪器、服务和软体。耗材和试剂部分重点在于抗生素检测板、培养基和PCR试剂盒，每种产品在监测管道中都发挥特定作用，并具有各自独特的供应和检验要求。仪器涵盖多种平台，从手动抗菌药物敏感性试验（AST）台到全自动系统和质谱仪。同时，服务和软体支援远端数据分析、品质保证以及将监测结果整合到临床决策支援系统中。

针对特定区域的分析揭示了地理位置相关的基础设施、采购结构和製造能力如何影响监控设定和供应商策略。

区域趋势对监测重点、供应链以及诊断技术的应用轨迹有显着影响。本节将综合分析关键区域的具体背景及其战略意义。在美洲，完善的公共卫生基础设施和集中式参考实验室为定序和自动化药敏试验的高普及率提供了支持，而采购週期和报销机制则影响着供应商的合作模式。此外，北美和南美的区域互联互通促进了疫情监测和数据共用的合作网络，这反过来又影响着供应商如何定位其整合硬体/软体解决方案和服务产品。

本次演讲将为企业提供可操作的见解，帮助其利用整合平台、供应链弹性和伙伴关係模式，重新定义监控解决方案的竞争优势。

在抗菌素抗药性监测领域营运的公司正从单一产品策略转向整合硬体、试剂、资讯科学和服务的一体化解决方案。本节将重点放在定义其竞争地位的策略倡议。领先的诊断和生命科学供应商正在投资开发支援表型和基因型检测管道的模组化平台，使客户能够简化工作流程并降低复杂性。同时，专业试剂公司正在开发检验的检测组合，以简化监管合规性并加速在各种实验室环境中的部署。随着互通性和数据分析成为寻求端到端监测能力的客户的关键差异化因素，仪器製造商和软体开发商之间的策略联盟正变得越来越普遍。

为高阶主管和职能领导者提供切实可行的、影响深远的建议，以增强其营运中监测系统的韧性、互通性和临床效用。

产业领导者必须采取重点突出、切实可行的策略，将监测情报转化为营运韧性和临床影响力。本节概述了针对高阶经营团队和职能领导者的量身定制、影响深远的建议。首先，优先考虑供应商多元化和合约机制，以确保关键耗材和备件的供应，同时避免依赖单一供应商。发展区域供应商关係并采用灵活的采购模式将显着降低营运风险。其次，投资可互通的资料架构和检验的分析工具，将检查室数据与临床和公共卫生系统连接起来。互通性能够实现跨组织边界的快速检测、集中监测和协调响应。第三，加快有针对性的自动化和数位化工作流程，以减少重复性高技能任务，同时提高可重复性和效率。透过自动化和能力建构相结合的方式，保持深厚的人才储备。

我们采用透明且可复製的调查方法，结合相关人员访谈、文献综合、专家检验和跨区域比较，得出可靠的结论。

本分析的调查方法融合了定性和定量方法，以确保得出可靠的实证结论，同时保持资料来源和检验过程的透明度。主要研究包括对检查室主任、采购负责人、临床微生物学家、公共卫生负责人和技术供应商进行结构化访谈，以收集有关营运挑战、采购行为和技术应用障碍的第一手资料。此外，还对同行评审文献、监管指南、技术白皮书和已发表的临床检验研究进行了全面审查，这些研究详细介绍了检测性能特征和工作流程整合方面的考虑因素。

关键整合强调在技术、互通性和供应韧性方面的协调投资，以保障治疗效果和公共卫生结果。

总之，抗菌素抗药性监测正从单一检查室的活动转变为涵盖临床护理、公共卫生、食品安全和环境监测的协作式、数据驱动型系统。快速表型分析、定序和数位分析等技术的进步使得监测讯号更加丰富，介入措施也更加迅速，但要充分发挥这些潜力，需要对互通性、人员能力和供应链韧性进行有意识的投资。政策变化、采购压力和不断演变的商业模式的综合影响，迫使各组织在短期营运连续性和长期能力建设之间寻求平衡。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 新兴的基于 CRISPR 的新型诊断工具可用于临床环境中快速检测抗菌药物抗药性
  • 将人工智慧和机器学习技术整合到监测网路中，用于预测抗菌素抗药性建模
  • 利用全基因组定序阐明社区中多重抗药性细菌的传播途径
  • 扩大社区污水监测计划，以识别都市区新出现的抗药性基因
  • 监管机构推动建立标准化的全球报告框架，以协调抗菌素抗药性数据共用通讯协定
  • 在资源匮乏的环境中推广照护现场分子检测，以实现分散式抗菌药物抗药性检测。
  • 製药公司与学术机构进行策略合作，加速发现针对抗药性病原体的新型抗生素
  • 实施「同一健康」倡议，整合人类、动物和环境抗菌素抗药性监测数据，以进行全面的风险评估

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

8. 按产品/服务分類的抗菌素抗药性监测市场

  • 耗材和试剂
    • 抗生素检测
    • 培养基
    • PCR试剂盒
  • 装置
  • 服务
  • 软体

9. 按技术分類的抗菌素抗药性监测市场

  • 自动化抗生素敏感性测试系统
  • 手动抗生素敏感性试验
  • 质谱分析
  • 下一代定序
  • 即时PCR

第十章：抗菌素抗药性监测市场（按应用领域划分）

  • 环境监测
  • 流行病学监测
  • 食品安全检查
  • 感染控制

第十一章 依最终用户分類的抗菌素抗药性监测市场

  • 学术研究机构
  • 临床检查室
  • 医院检查室
  • 製药和生物技术公司
  • 参考检查室

12. 按地区分類的抗菌素抗药性监测市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 按组别分類的抗菌素抗药性监测市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国抗菌素抗药性监测市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Thermo Fisher Scientific, Inc.
    • F. Hoffmann-La Roche Ltd
    • Becton, Dickinson and Company
    • bioMerieux SA
    • QIAGEN NV
    • Illumina, Inc.
    • bio-Rad Laboratories, Inc.
    • Siemens Healthineers AG
    • Merck KGaA
    • Accelerate Diagnostics, Inc.
Product Code: MRR-CF6C60CF95A8

The Antimicrobial Resistance Surveillance Market is projected to grow by USD 10.01 billion at a CAGR of 6.70% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.96 billion
Estimated Year [2025] USD 6.36 billion
Forecast Year [2032] USD 10.01 billion
CAGR (%) 6.70%

A compelling introduction that frames antimicrobial resistance surveillance as an urgent clinical, technological, and systems-level priority requiring integrated diagnostics and data

Antimicrobial resistance surveillance sits at the intersection of clinical urgency, technological advancement, and public health strategy, requiring a coherent introduction that frames the challenge and the evolving response landscape. The opening assessment synthesizes why coordinated surveillance is foundational to preserving therapeutic efficacy: rising resistance profiles among bacterial pathogens are reshaping diagnostic priorities, accelerating demand for rapid phenotypic and genotypic testing, and forcing laboratories and health systems to reconsider how data is collected, analyzed, and shared across networks. In addition to clinical implications, surveillance systems are increasingly central to food safety, environmental monitoring, and epidemiological intelligence, thereby broadening the stakeholder base and amplifying requirements for interoperable data standards and secure information exchange.

Moreover, the contemporary introduction emphasizes the convergence of instrumentation, consumables, informatics, and services as integral components of an effective surveillance ecosystem. Diagnostic manufacturers, reagent suppliers, software developers, and service providers must coordinate to deliver integrated solutions that support real-time decision making. This introduction also acknowledges the operational pressures felt by laboratories, including workforce constraints, supply chain volatility, and regulatory requirements, while underscoring how investments in automation, sequencing, and analytics can enhance throughput and generate higher-fidelity surveillance signals. Ultimately, the introduction sets the stage for a report that balances technical detail with strategic implications, positioning surveillance as both a clinical necessity and a systems-level capability that demands sustained investment and cross-sector collaboration

Insightful analysis of the major technological, operational, and policy-driven shifts reshaping antimicrobial resistance surveillance systems worldwide

The landscape for antimicrobial resistance surveillance is undergoing transformative shifts driven by technological maturation, policy momentum, and changing stakeholder expectations, and this section details the principal vectors of change. Advances in rapid phenotypic testing and high-throughput sequencing have shortened the time from sample to actionable insight, enabling more precise antimicrobial stewardship and earlier detection of emerging resistance patterns. Concurrently, digital health platforms and laboratory information systems are enabling richer data linkages across clinical, public health, food safety, and environmental domains, reinforcing the shift from isolated testing events to continuous surveillance streams. These technological changes are complemented by growing regulatory scrutiny and heightened expectations for data transparency, prompting organizations to strengthen validation pathways and invest in interoperability standards.

In parallel, an operational recalibration is occurring across supply chains and service models. Laboratories are balancing in-house capability expansion with outsourced testing partnerships, while manufacturers are rethinking production flexibility and distribution strategies to mitigate supply disruptions. Workforce dynamics are also shifting: skilled laboratory professionals face increased demand, and organizations are deploying automation and remote-support models to preserve capacity. Taken together, these trends are not simply incremental; they are altering how surveillance programs are designed, funded, and operated. Decision-makers must therefore adapt governance models, invest in resilient supply relationships, and prioritize technologies that integrate seamlessly into existing clinical and public health workflows

Comprehensive evaluation of how recent tariff shifts are altering procurement dynamics, supply resilience strategies, and operational planning across surveillance ecosystems

The cumulative effect of tariff measures enacted in 2025 has introduced new variables into the procurement calculus for diagnostics, reagents, and laboratory instrumentation, and this section traces the practical implications without presuming numerical projections. Higher import duties and related trade policy measures have intensified the cost pressures on laboratories and health systems that rely on cross-border supply chains for critical consumables and complex instruments. In response, procurement teams and supplier organizations have increasingly prioritized diversification of sourcing, localized manufacturing partnerships, and inventory optimization strategies aimed at reducing single-country dependency. At the same time, these trade shifts have reinforced the attractiveness of service-based delivery models and reagent rental programs that can buffer facilities from capital expenditure volatility.

Regulatory and compliance burdens have also been affected, as increased tariffs may trigger adjustments in supplier contracts, customs processes, and lead-time expectations, necessitating more rigorous supplier performance monitoring and contractual protections. For manufacturers, the tariff environment has accelerated strategic decisions around regional manufacturing footprints and tariff engineering to preserve competitiveness. Health systems and reference labs are consequently adapting by strengthening demand forecasting, expanding collaborative purchasing consortia, and exploring homologation strategies to qualify alternative suppliers more rapidly. Importantly, these responses underscore a broader trend toward supply chain resilience and operational flexibility, where procurement agility and supplier transparency become as critical as product performance in sustaining effective antimicrobial resistance surveillance

In-depth segmentation insights revealing how product offerings, technologies, applications, and end-user needs collectively determine surveillance priorities and procurement behaviors

Key segmentation insights illuminate how distinct product, technology, application, and end-user dimensions intersect to shape procurement priorities, operational workflows, and investment choices within antimicrobial resistance surveillance. When examining the market by offering, the landscape spans consumables and reagents, instruments, services, and software; within consumables and reagents, attention centers on antibiotic panels, culture media, and PCR kits, each of which plays a specific role in surveillance pathways and has discrete supply and validation requirements. Instruments encompass a range of platforms from manual AST benches to fully automated systems and mass spec analyzers, while services and software enable remote data interpretation, quality assurance, and the integration of surveillance outputs into clinical decision support systems.

From a technology perspective, automated antimicrobial susceptibility testing systems, manual AST methods, mass spectrometry platforms, next-generation sequencing workflows, and real-time PCR assays present distinct trade-offs in turnaround time, sensitivity, and operational complexity. Applications drive adoption priorities differently: environmental monitoring emphasizes robust sample handling and throughput, epidemiological surveillance prioritizes data continuity and lineage tracing, food safety testing requires stringent traceability, and infection control focuses on rapid detection at the point of care or within hospital laboratories. End users further shape procurement and deployment models: academic and research institutes value configurability and depth of data, clinical laboratories and hospital laboratories prioritize throughput and regulatory compliance, pharmaceutical and biotechnology companies require stringent controls for development programs, and reference laboratories demand scalable, high-volume platforms. Understanding these segmentation dynamics is essential for aligning product development, commercialization strategies, and service models with the real-world needs of diverse stakeholders

Targeted regional analysis that clarifies how geographically specific infrastructure, purchasing frameworks, and manufacturing capabilities shape surveillance implementation and supplier strategies

Regional dynamics exert strong influence on surveillance priorities, supply chains, and the adoption curve for diagnostic technologies; this section synthesizes the distinct conditions and strategic implications across major geographies. In the Americas, established public health infrastructures and a concentration of reference laboratories support advanced adoption of sequencing and automated susceptibility testing, while procurement cycles and reimbursement frameworks shape supplier engagement models. Furthermore, regional interconnectivity in North and South America has prompted collaborative networks for outbreak detection and data sharing, which in turn influence how vendors position integrated hardware-software solutions and service offerings.

Across Europe, the Middle East and Africa, heterogeneity defines both challenge and opportunity. Well-resourced systems in parts of Western Europe have accelerated adoption of data-driven surveillance platforms and value digital interoperability, whereas resource-constrained settings in other parts of the region prioritize affordability, robustness, and ease of use. As a result, suppliers tailor portfolios to meet a wide spectrum of needs, often combining low-complexity, high-reliability assays with scalable software tools. In the Asia-Pacific region, diverse manufacturing capabilities, rapid technology diffusion, and significant investments in public health genomics create a dynamic marketplace for sequencing, real-time PCR, and automated AST solutions. Regional supply chain capabilities and domestic production policies also influence procurement choices, making local partnership strategies and flexible commercial models particularly effective for achieving deployment at scale

Actionable company-level insights highlighting how integrated platforms, supply resilience, and partnership models are redefining competitive advantage in surveillance solutions

Companies operating in the antimicrobial resistance surveillance space are evolving beyond single-product strategies toward integrated solution sets that combine hardware, reagents, informatics, and services, and this section distills the strategic moves that define competitive positioning. Leading diagnostic and life-science suppliers are investing in modular platforms that support both phenotypic and genotypic testing pathways, enabling clients to consolidate workflows and reduce complexity. At the same time, reagent specialists are developing validated assay panels that simplify regulatory compliance and accelerate deployment across heterogeneous laboratory environments. Strategic partnerships between instrument manufacturers and software developers are increasingly common, as interoperability and data analytics become critical differentiators for customers seeking end-to-end surveillance capabilities.

Additionally, many organizations are strengthening supply chain transparency and resilience through regional manufacturing, multi-sourcing strategies, and service contracts that bundle consumables with training and remote support. Sales and commercialization teams are adapting by offering flexible procurement models, including subscription and reagent-rental arrangements, which can lower adoption barriers for resource-constrained facilities. R&D priorities among companies reflect an emphasis on faster time-to-result, improved analytical sensitivity, and streamlined sample-to-answer workflows, while commercial strategies emphasize integrated clinical validation and health-economics evidence to support adoption. Together, these company-level trends signal a maturing market where technological breadth, supply reliability, and data integration increasingly determine competitive advantage

Practical, high-impact recommendations for executives and functional leaders to strengthen surveillance resilience, interoperability, and clinical utility across operations

Industry leaders must adopt focused, pragmatic strategies to translate surveillance intelligence into operational resilience and clinical impact, and this section outlines a set of high-impact recommendations tailored to senior executives and functional leaders. First, prioritize supplier diversification and contractual mechanisms that secure critical consumables and spare parts without locking organizations into single-source dependencies; building regional supplier relationships and embracing flexible procurement models can materially reduce operational risk. Second, invest in interoperable data architectures and validated analytics that connect laboratory outputs with clinical and public health systems; interoperability enables faster detection, centralized monitoring, and coordinated responses across institutional boundaries. Third, accelerate targeted automation and digital workflows that relieve skilled personnel from repetitive tasks while improving reproducibility and throughput; combine automation with competency development programs to maintain workforce depth.

Fourth, realign product and service portfolios around modular integration, ensuring that instruments, reagents, and software can be deployed in layered configurations that meet diverse end-user needs. Fifth, embed regulatory and quality assurance planning into product roadmaps to streamline approvals and enhance trust among clinical customers. Finally, foster collaborative models with public health agencies, academic centers, and industry partners to co-develop sentinel surveillance projects and pilot implementations; these collaborations generate operational evidence, validate real-world performance, and create pathways for scaled adoption. Implementing these recommendations requires disciplined governance, prioritized investment, and a focus on measurable outcomes tied to clinical utility and system resilience

Transparent and reproducible research methodology combining stakeholder interviews, literature synthesis, expert validation, and cross-regional comparison to support robust conclusions

The research methodology underpinning this analysis blends qualitative and quantitative approaches to ensure robust, evidence-based conclusions while maintaining transparency about data sources and validation processes. Primary research included structured interviews with laboratory leaders, procurement specialists, clinical microbiologists, public health officials, and technology vendors to capture first-hand perspectives on operational challenges, procurement behaviors, and technology adoption barriers. These insights were supplemented by a comprehensive review of peer-reviewed literature, regulatory guidance, technical whitepapers, and published clinical validation studies that detail assay performance characteristics and workflow integration considerations.

To ensure analytical rigor, findings were triangulated across multiple sources and subjected to expert validation rounds, where independent subject-matter experts reviewed assumptions, interpreted technical trade-offs, and assessed the operational feasibility of recommended actions. The methodology also incorporated cross-regional comparisons to highlight contextual differences and to identify where localized strategies are necessary. Limitations include variability in reporting standards across institutions and the evolving nature of regulatory pathways for new diagnostic modalities, which were addressed through conservative interpretation of qualitative data and transparent documentation of data provenance. Overall, the methodological approach emphasizes reproducibility, stakeholder validation, and the translation of technical evidence into actionable strategic guidance

Conclusive synthesis emphasizing coordinated investment in technology, interoperability, and supply resilience to protect therapeutic efficacy and public health outcomes

In conclusion, antimicrobial resistance surveillance is transitioning from a collection of discrete laboratory activities into a coordinated, data-driven system that spans clinical care, public health, food safety, and environmental monitoring. Technological advances in rapid phenotypic testing, sequencing, and digital analytics are enabling richer surveillance signals and faster interventions, but realizing this potential requires intentional investment in interoperability, workforce capacity, and supply chain resilience. The confluence of policy changes, procurement pressures, and evolving commercial models means that organizations must balance near-term operational continuity with longer-term capability building.

The synthesis underscores the importance of modular solutions that can be adapted to diverse laboratory settings, the necessity of diversified supplier strategies in the face of trade and tariff disruption, and the strategic value of integrated software and service offerings that translate raw data into actionable insights. Leaders who proactively align procurement, technology adoption, and governance will be better positioned to detect emerging resistance trends, support antimicrobial stewardship programs, and protect patient outcomes. This conclusion is a call to action for coordinated effort across manufacturers, laboratories, policymakers, and funders to prioritize surveillance as a foundational public health asset

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of novel CRISPR-based diagnostic tools for rapid AMR detection in clinical settings
  • 5.2. Integration of artificial intelligence and machine learning for predictive antibiotic resistance modeling in surveillance networks
  • 5.3. Adoption of whole genome sequencing to map regional multidrug resistant bacterial transmission pathways
  • 5.4. Expansion of community wastewater surveillance programs to identify emerging resistance genes in urban populations
  • 5.5. Regulatory push for standardized global reporting frameworks to unify antimicrobial resistance data sharing protocols
  • 5.6. Growth of point-of-care molecular assays enabling decentralized AMR testing in resource-limited environments
  • 5.7. Strategic partnerships between pharmaceutical companies and academic institutions to accelerate novel antibiotic discovery targeting resistant pathogens
  • 5.8. Implementation of One Health initiatives linking human, animal, and environmental AMR surveillance data for holistic risk assessments

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antimicrobial Resistance Surveillance Market, by Offering

  • 8.1. Consumables And Reagents
    • 8.1.1. Antibiotic Panels
    • 8.1.2. Culture Media
    • 8.1.3. PCR Kits
  • 8.2. Instruments
  • 8.3. Services
  • 8.4. Software

9. Antimicrobial Resistance Surveillance Market, by Technology

  • 9.1. Automated AST Systems
  • 9.2. Manual AST
  • 9.3. Mass Spectrometry
  • 9.4. Next Generation Sequencing
  • 9.5. Real Time PCR

10. Antimicrobial Resistance Surveillance Market, by Application

  • 10.1. Environmental Monitoring
  • 10.2. Epidemiological Surveillance
  • 10.3. Food Safety Testing
  • 10.4. Infection Control

11. Antimicrobial Resistance Surveillance Market, by End User

  • 11.1. Academic And Research Institutes
  • 11.2. Clinical Laboratories
  • 11.3. Hospital Laboratories
  • 11.4. Pharmaceutical And Biotechnology Companies
  • 11.5. Reference Laboratories

12. Antimicrobial Resistance Surveillance Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Antimicrobial Resistance Surveillance Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Antimicrobial Resistance Surveillance Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Thermo Fisher Scientific, Inc.
    • 15.3.2. F. Hoffmann-La Roche Ltd
    • 15.3.3. Becton, Dickinson and Company
    • 15.3.4. bioMerieux SA
    • 15.3.5. QIAGEN N.V.
    • 15.3.6. Illumina, Inc.
    • 15.3.7. bio-Rad Laboratories, Inc.
    • 15.3.8. Siemens Healthineers AG
    • 15.3.9. Merck KGaA
    • 15.3.10. Accelerate Diagnostics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ANTIBIOTIC PANELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ANTIBIOTIC PANELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ANTIBIOTIC PANELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ANTIBIOTIC PANELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ANTIBIOTIC PANELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ANTIBIOTIC PANELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CULTURE MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CULTURE MEDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CULTURE MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CULTURE MEDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CULTURE MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CULTURE MEDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PCR KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PCR KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PCR KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PCR KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PCR KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PCR KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY AUTOMATED AST SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY AUTOMATED AST SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY AUTOMATED AST SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY AUTOMATED AST SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY AUTOMATED AST SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY AUTOMATED AST SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MANUAL AST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MANUAL AST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MANUAL AST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MANUAL AST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MANUAL AST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MANUAL AST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ENVIRONMENTAL MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ENVIRONMENTAL MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ENVIRONMENTAL MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ENVIRONMENTAL MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ENVIRONMENTAL MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ENVIRONMENTAL MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY FOOD SAFETY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY FOOD SAFETY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY FOOD SAFETY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY FOOD SAFETY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY FOOD SAFETY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY FOOD SAFETY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INFECTION CONTROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INFECTION CONTROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INFECTION CONTROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INFECTION CONTROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INFECTION CONTROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INFECTION CONTROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 244. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 245. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 246. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 256. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 257. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 258. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 259. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 261. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 262. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 263. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION ANTIMICROBIAL